Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma

Journal of Pathology: Clinical Research

Volumn 2, Issue 4, 2016, Pages 247-258

  Köbel, Martin ^a   Piskorz, Anna M ^b   Lee, Sandra ^a   Lui, Shuhong ^a   LePage, Cecile ^c,d   Marass, Francesco ^b   Rosenfeld, Nitzan ^b   Masson, Anne Marie Mes ^c,d   Brenton, James D ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d Institut du Cancer de Montreal   (Canada)

Author keywords

Biomarker; Endometrioid ovarian carcinoma; High grade serous ovarian carcinoma; Immunohistochemistry; Next generation sequencing; P53; Prediction; TP53

Indexed keywords

PROTEIN P53;

ACCURACY; ADULT; ARTICLE; CANCER GRADING; CONTROLLED STUDY; FEMALE; GAIN OF FUNCTION MUTATION; GENE; GENE DELETION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INDEPENDENT VARIABLE; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MIDDLE AGED; NEXT GENERATION SEQUENCING; OVARY CARCINOMA; PREDICTIVE VALUE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; TP53 GENE;

EID: 85009202117     PISSN: None     EISSN: 20564538     Source Type: Journal    
DOI: 10.1002/cjp2.53     Document Type: Article

References (56)

1. Ahmed AA, Etemadmoghadam D, Temple J, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 2010; 221: 49-56.
2. Lee Y, Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 2007; 211: 26-35.
3. Kuhn E, Kurman RJ, Vang R, et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma-evidence supporting the clonal relationship of the two lesions. J Pathol 2011; 226: 421-426.
4. Chien J, Sicotte H, Fan JB, et al. TP53 mutations, tetraploidy and homologous recombination repair defects in early. Nucleic Acids Res 2015; 43: 6945-6958.
5. Bashashati A, Ha G, Tone A, et al. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J Pathol 2013; 231: 21-34.
6. Castellarin M, Milne K, Zeng T, et al. Clonal evolution of high-grade serous ovarian carcinoma from primary to recurrent disease. J Pathol 2013; 229: 515-524.
7. Schwarz RF, Ng CK, Cooke SL, et al. Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis. PLoS Med 2015; 12: e1001789.
8. Swisher EM, Wollan M, Mahtani SM, et al. Tumor-specific p53 sequences in blood and peritoneal fluid of women with. Am J Obstet Gynecol 2005; 193: 662-667.
9. Forshew T, Murtaza M, Parkinson C, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 2012; 4: 136ra68.
10. Altman AD, Nelson GS, Ghatage P, et al. The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors. Mod Pathol 2013; 26: 1255-1263.
11. Murtaza M, Dawson S-J, Tsui DWY, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013; 497: 108-112.
12. McManus DT, Yap EP, Maxwell P, et al. p53 expression, mutation, and allelic deletion in ovarian cancer. J Pathol 1994; 174: 159-168.
13. Casey G, Lopez ME, Ramos JC, et al. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene 1996; 13: 1971-1981.
14. Leitao MM, Soslow RA, Baergen RN, et al. Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma. Gynecol Oncol 2004; 93: 301-306.
15. Nenutil R, Smardova J, Pavlova S, et al. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. J Pathol 2005; 207: 251-259.
16. Singer G, Stöhr R, Cope L, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low-and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 2005; 29: 218-224.
17. de Graeff P, Crijns APG, de Jong S, et al. Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis. Br J Cancer 2009; 101: 149-159.
18. Köbel M, Reuss A, du Bois A, et al. The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J Pathol 2010; 222: 191-198.
19. Köbel M, Rahimi K, Rambau PF, et al. An Immunohistochemical Algorithm for Ovarian Carcinoma Typing. Int J Gynecol Pathol 2016; 35: 430-441.
20. Yemelyanova A, Vang R, Kshirsagar M, et al. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol 2011; 24: 1248-1253.
21. Muller PAJ, Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell 2014; 25: 304-317.
22. Bieging KT, Mello SS, Attardi LD. Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer 2014; 14: 359-370.
23. Zhu J, Sammons MA, Donahue G, et al. Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. Nature 2015; 525: 206-211.
24. Olive KP, Tuveson DA, Ruhe ZC, et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004; 119: 847-860.
25. Lang GA, Iwakuma T, Suh Y-A, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004; 119: 861-872.
26. Shahin MS, Hughes JH, Sood AK, et al. The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer 2000; 89: 2006-2017.
27. Wojnarowicz PM, Oros KK, Quinn MCJ, et al. The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcome. PLoS One 2012; 7: e45484.
28. Lehmann S, Bykov VJN, Ali D, et al. Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol 2012; 30: 3633-3639.
29. Maslon MM, Hupp TR. Drug discovery and mutant p53. Trends Cell Biol 2010; 20: 542-555.
30. Wiman KG. Pharmacological reactivation of mutant p53: from protein structure to the cancer patient. Oncogene 2010; 29: 4245-4252.
31. Gourley C, Gabra H, Vergote I, et al. EUTROC PiSARRO: a phase Ib study combining APR-246 with standard chemotherapy in platinum sensitive relapsed high grade serous ovarian carcinoma (HGSOC). In ASCO Annual Meeting Proceedings 2015; 33: TPS5605.
32. Martin L, Grigoryan A, Wang D, et al. Identification and characterization of small molecules that inhibit nonsense-mediated RNA decay and suppress nonsense p53 mutations. Cancer Res 2014; 74: 3104-3113.
33. Bykov VJN, Wiman KG. Mutant p53 reactivation by small molecules makes its way to the clinic. FEBS Lett 2014; 588: 2622-2627.
34. Le Page, Kobel M, de Ladurantaye, et al. Specimen quality evaluation in Canadian biobanks participating in the COEUR. Biopreserv Biobank 2013; 11: 83-93.
35. Bromley AB, Altman AD, Chu P, et al. Architectural patterns of ovarian/pelvic high-grade serous carcinoma. Int J Gynecol Pathol 2012; 31: 397-404.
36. Thorvaldsdottir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization. Briefing Bioinform 2013; 14: 178-192.
37. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314: 268-274.
38. Barber BR, Biron VL, Klimowicz AC, et al. Molecular predictors of locoregional and distant metastases in oropharyngeal squamous cell carcinoma. J Otolaryngol Head Neck Surg 2013; 42: 53.
39. R Core Team (2015). R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. [Accessed 1 September 2015]: available from: https://www.R-project.org/
40. Caret: Classification and Regression Training. R package version 6.0-52. [Accessed 1 September 2015]: available from: https://cran.r-project.org/web/packages/caret/index.html
41. Stodden V, Leisch F, Peng RD. Implementing Reproducible Research. Chapman and Hall/CRC. London, UK. 2014; 1-448.
42. Bell D, Berchuck A, Birrer M, et al. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-615.
43. McAlpine JN, Porter H, Köbel M, et al. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. Mod Pathol 2012; 25: 740-750.
44. Lee S, Piskorz AM, Le Page C, et al. Calibration and optimization of p53, WT1, and Napsin A immunohistochemistry ancillary tests for histotyping of ovarian carcinoma: Canadian Immunohistochemistry Quality Control (CIQC) experience. Int J Gynecol Pathol 2016; 35: 209-221.
45. Cooks T, Pateras IS, Tarcic O, et al. Mutant p53 prolongs NFkappaB activation and promotes chronic inflammation and. Cancer Cell 2013; 23: 634-646.
46. Jansson A, Gentile M, Sun XF. p53 Mutations are present in colorectal cancer with cytoplasmic p53 accumulation. Int J Cancer 2001; 92: 338-341.
47. Komlodi-Pasztor E, Trostel S, Sackett D, et al. Impaired p53 binding to importin: a novel mechanism of cytoplasmic sequestration identified in oxaliplatin-resistant cells. Oncogene 2009; 28: 3111-3120.
48. Green DR, Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature 2009; 458: 1127-1130.
49. Visvanathan K, Vang R, Shaw P, et al. Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: a reproducibility study. Am J Surg Pathol 2011; 35: 1766-1775.
50. Han G, Sidhu D, Duggan MA, et al. Reproducibility of histological cell type in high-grade endometrial carcinoma. Mod Pathol 2013; 26: 1594-1604.
51. Kaye PV, Haider SA, James PD, et al. Novel staining pattern of p53 in Barrett’s dysplasia - the absent pattern. Histopathology 2010; 57: 933-935.
52. Singh N, Leen SL, Han G, et al. Expanding the morphologic spectrum of differentiated VIN (dVIN) through detailed mapping of cases with p53 loss. Am J Surg Pathol 2015; 39: 52-60.
53. Vang R, Levine DA, Soslow RA, et al. Molecular Alterations of TP53 are a defining feature of ovarian high-grade serous carcinoma: a rereview of cases lacking TP53 mutations in the cancer genome atlas ovarian study. Int J Gynecol Pathol 2015; 35: 48-55.
54. McConechy MK, Ding J, Senz J, et al. Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles. Mod Pathol 2013; 27: 128-134.
55. Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497: 67-73.
56. Wu R, Hendrix-Lucas N, Kuick R, et al. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and P13K/Pten signaling pathways. Cancer Cell 2007; 11: 321-333.